Clinical Trials Logo

EGFR-TKI Resistant Mutation clinical trials

View clinical trials related to EGFR-TKI Resistant Mutation.

Filter by:
  • None
  • Page 1

NCT ID: NCT06363734 Recruiting - Clinical trials for Non-small Cell Lung Cancer

Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial

Start date: April 9, 2024
Phase: Phase 2
Study type: Interventional

This study is a prospective, single-arm, phase II trial. It is aimed to evaluate the efficacy and safety of the combination of osimertinib and dalpiciclib in patients with EGFR-mutant, CDK4/6 pathway aberrant, advanced NSCLC following acquired resistance to third-generation EGFR TKI.

NCT ID: NCT06071013 Not yet recruiting - Clinical trials for Non-small Cell Lung Cancer

Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

Start date: September 28, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Nintedanib with EGFR-TKI in participants with advanced EGFR-TKI-resistant non-small cell lung cancer

NCT ID: NCT05598528 Recruiting - EGFR Gene Mutation Clinical Trials

Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)

PRECISE
Start date: September 28, 2021
Phase:
Study type: Observational [Patient Registry]

Lung cancer is currently the world's largest malignant tumor for cancer-related deaths with non-small cell lung cancer (NSCLC) accounting for 80%-85%. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), especially the 3rd-generation EGFR-TKIs have demonstrated strong antitumor effects in EGFR-positive patients. However, approximately 20% of EGFR-positive were primarily resistant to 3rd generation EGFR-TKIs, i.e., clinical non-response or disease progression in the short term. This study aimed to clarify the molecular indicators that predict the benefits of 3-rd EGFR-TKIs as first-line therapy in NSCLCpatients with EGFR-positive. Further, to clarify their primary drug resistance mechanisms, which is of great significance for the treatment and clinical decision-making of NSCLC disease.

NCT ID: NCT05256290 Recruiting - Clinical trials for Non-Small Cell Lung Cancer

Phase 1/2 Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

Start date: March 31, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

BDTX-1535-101 is an open-label, Phase 1 dose escalation and Phase 2 multiple cohort study designed to evaluate the safety, pharmacokinetics (PK), optimal dosage, central nervous system (CNS) activity, and antitumor activity of BDTX-1535. The study population comprises adults with either advanced/metastatic non-small cell lung cancer (NSCLC) with non-classical or acquired epidermal growth factor receptor (EGFR) resistance (EGFR C797S) mutations with or without CNS disease (in Phase 1 and Phase 2), or glioblastoma (GBM) expressing EGFR alterations (Phase 1 only). All patients will self-administer BDTX-1535 monotherapy by mouth in 21-day cycles. Phase 1 enrollment is now complete. Phase 2 is currently enrolling.

NCT ID: NCT02972333 Not yet recruiting - Brain Metastases Clinical Trials

Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M

Start date: December 2016
Phase: Phase 3
Study type: Interventional

The study aims to investigate the efficacy and safety of AZD9291 in brain metastases from patients with EGFR T790M positive NSCLC who have received prior therapy with an EGFR-TKI.

NCT ID: NCT02661009 Not yet recruiting - Clinical trials for Non Small Cell Lung Cancer

Human EGFR Mutations Quantitative Detection Kit (Real-time Fluorescent PCR Method)

Start date: January 2016
Phase: N/A
Study type: Observational

In this clinical trial, investigators select FFPE and plasma samples of non-small cell lung cancer which are used for quantitative detection of four kinds of EGFR(Epidermal Growth Factor Receptor) mutations. By the following two aspects, investigators evaluate the clinical performance of the EGFR quantitative kits. 1. methodology validation: To certify the equivalence between the EGFR quantitative kit and the common used detection methods. 2. analysis of the relationship between the type and proportion of EGFR sensitive mutation and EGFR-TKI benefit.

NCT ID: NCT02575560 Completed - Clinical trials for EGFR-TKI Resistant Mutation

Weekly Use First-generation EGFR-TKI in the Treatment of EGFR-TKI Acquired Resistance Non-small Cell Lung Cancer (NSCLC)

Start date: October 1, 2015
Phase: N/A
Study type: Observational

EGFR-TKI is the main is the first line therapy for local advanced or metastatic non-small cell lung cancer with EGFR gene mutation. The median progression free survival time is around 11 months with the first generation EGFR-TKI. Patients with acquired resistance with first generation EGFR-TKI usually with EGFR exon 20 mutation (T790M). Change the drug administration maybe prolong patients PFS and evently prolong OS.

NCT ID: NCT01994057 Recruiting - Clinical trials for Non-small Cell Lung Cancer (NSCLC)

A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment

Start date: September 2012
Phase:
Study type: Observational

For patients of advanced NSCLC (non small cell lung cancer) , Individualized cancer therapy has been widely accepted since the success of crizotinib administration based on EML4-ALK fusion gene detection and gefitinib and erlotinib administration based on EGFR-TKIs sensitive mutations.From clinical points of view ,individual differences often occur between different patients, leading diverse effect in ADR and drug effect.Meanwhile ,the drug effect and adverse drug reaction was significantly influenced by the pharmacokinetic factors and pharmacodynamic factors.In this research ,we try to establish a more sensitive method to detect sensitive mutations in plasma and discover the correlation between somatic and germline mutations , trough concentration and EGFR-TKI drug effect, the association between ADME-associated SNP ,trough concentration and EGFR-TKI adverse effect .Furthermore, in vivo and in vitro research is also crucial for rational explanation for these clinical phenomenon.